Breaking News on Contract Research, Manufacturing & Clinical Trials

Go

Product innovations > Supplier info center

SGS Life Science Services

SGS' Life Science Services has 30 years of experience as a global contract service organization providing integrated solutions from preclinical activities to Phase I-IV trials, bioanalytical and QC testing. With more than 1,300 employees and 2,000 clinical trials performed, SGS serves the pharmaceutical, biotechnology and medical device industries.


With broad expertise and experience, SGS understands clients' needs, anticipates challenges and consistently delivers high quality results on time, enabling clients to improve efficiency in drug development and manufacturing.


SGS' state of the art facilities include: two Phase I units with a total of 162 beds, four bioanalytical labs, and a network of Phase II-IV clinical trial management offices throughout Europe, North America and Asia.


Through years of executing complex trials SGS has a wealth of expertise in:


  • QT/QTc prolongation, radio-labeled C14 ADME & PET scan trials
  • Rapid access to special patient populations provides clients with the recruitment edge to execute time-critical trials, including: pediatric, renal & hepatic impaired, postmenopausal and sterilized women, elderly and slow metabolizer patients)
  • Numerous therapeutic areas with a particular focus on Infectious diseases, including HIV and vaccines, Respiratory, Cardiac and Neurological diseases

SGS offers extensive Bioanalytical capabilities and services, featuring mass spectrometry and immunoanalysis; including R&D capabilities for NCE's, hormones & biomarkers and a library of over 600 methods.


SGS' Biometrics team support Phase I-IV clinical trials, with emphasis on biostatistics, data management, and medical writing. Clients benefit from a knowledgeable, proactive staff; experts in working in: Oracle Clinical® & ClinTrial®, CDISC & EDC.

More information

Related news headlines to SGS

News briefs: Green packaging initiatives

07-May-2008 - Pepsi reduces plastic in 500ml non-carbonated beverage bottle, Earthcycle expands its fresh produce compostable packaging line and the Reusable Pallet & Container Coalition changes its name to Reusable Packaging Association.

Canadian packaging group opts for ethical sourcing

18-Apr-2008 - Canada's Earthcycle, a producer of palm fibre-based packaging, has confirmed that its source material is made from sustainable sources that have not contributed to deforestation.

SGS launches supply chain safety services

30-Mar-2008 - SGS has officially launched a new auditing service designed to alleviate the quality, regulatory and safety issues in pharmaceutical supply chains, which are increasingly extending across the globe.

Broccoli compound boost for immune health

07-Mar-2008 - A compound found in broccoli, previously linked to anti-cancer benefits, may also counter the decline in the body's immune system associated with age, says a new study from UCLA.

Broccoli sprouts linked to bladder cancer protection

28-Feb-2008 - A concentrated extract from broccoli sprouts may cut the development of bladder cancer by more than 50 per cent, according to results of an animal study.

Results: 2007 European outsourcing awards

16-Oct-2007 - The ten winners of the European outsourcing awards for 2007 were finally unveiled at the recently-held CPhI trade show in Milan.

One audit, multiple certifications

25-Jul-2007 - One audit can achieve multiple food safety certifications under a new global service offered by a Switzerland-based company.

Eclinical news in brief

20-Mar-2007 - Outsourcing-Pharma tracks the latest eClinical movements, featuring SGS Phase Forward, Datatrak, Clinipace, etrials, CSS Informatics and Spheris.

Fenchem makes novel foods petition for Cholevel sterols

21-Sep-2006 - Chinese ingredients supplier Fenchem is seeking substantial equivalence for its Cholevel branded phytosterol under European novel foods legislation, which it expects will be a big spark for the product line.

Merck Sharp & Dohme Singapore investment tops S$1bn

07-Aug-2006 - Merck Sharp & Dohme (MSD) has invested $100m to expand its manufacturing plant in Singapore, bringing the drug giant's investment in this budding region to over S$1bn (€0.5bn).